Grant: Catalyst Grant: Musculoskeletal Health and Arthritis
McMaster University
$97,400.00
AMPK-mediated neuromuscular plasticity: Implications for the treatment of neuromuscular disorders
EF 2016-17
Résumé
Neuromuscular diseases (NMDs) represent a broad group of more than 150 genetic and acquired disorders, many of which are debilitating, progressive and cause premature death. Almost one million people in North America are believed to be affected by these disorders, which additionally have great socio-economic impact. Among the most prevalent NMDs are Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and myotonic dystrophy type I (DM1). For these NMDs, no cure or effective treatments exist. Several approaches have been envisaged to counteract the deleterious effects of these progressive disorders, including for example gene therapy and stem cell transfer. An alternative strategy consists of utilizing a protein normally expressed in the neuromuscular system, that when appropriately stimulated, could trigger a variety of beneficial adaptations in DMD, SMA, and DM1.
A candidate for such a role is adenosine monophosphate-activated protein kinase (AMPK) because it can initiate beneficial neuromuscular remodelling via the activation of a wide variety of molecular pathways that result in enhanced cellular protection. Therefore, studies aimed at further 1) characterizing AMPK biology in the compromised neuromuscular system of DMD, SMA, and DM1, and 2) deciphering the optimal therapeutic strategy for AMPK activation in these contexts, are warranted in order to advance toward addressing critical, unmet clinical needs in NMD patients.
Programme
Catalyst Grant: Musculoskeletal Health and Arthritis
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
364110
Name
Ljubicic Vladimir
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
MSK Health - Catalyst Grant IMHA
Projecttitle
AMPK-mediated neuromuscular plasticity: Implications for the treatment of neuromuscular disorders
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$97,400
Cihrequipment2
$0
Programname2
Catalyst Grant: Musculoskeletal Health and Arthritis
Keyworddelim
Ampk; Cellular And Molecular; Drugs; Duchenne Muscular Dystrophy; Exercise; Myotonic Dystrophy; Neuromuscular Disorders; Neuromuscular System; Pre-Clinical; Spinal Muscular Atrophy
Abstract
Neuromuscular diseases (NMDs) represent a broad group of more than 150 genetic and acquired disorders, many of which are debilitating, progressive and cause premature death. Almost one million people in North America are believed to be affected by these disorders, which additionally have great socio-economic impact. Among the most prevalent NMDs are Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and myotonic dystrophy type I (DM1). For these NMDs, no cure or effective treatments exist. Several approaches have been envisaged to counteract the deleterious effects of these progressive disorders, including for example gene therapy and stem cell transfer. An alternative strategy consists of utilizing a protein normally expressed in the neuromuscular system, that when appropriately stimulated, could trigger a variety of beneficial adaptations in DMD, SMA, and DM1.
A candidate for such a role is adenosine monophosphate-activated protein kinase (AMPK) because it can initiate beneficial neuromuscular remodelling via the activation of a wide variety of molecular pathways that result in enhanced cellular protection. Therefore, studies aimed at further 1) characterizing AMPK biology in the compromised neuromuscular system of DMD, SMA, and DM1, and 2) deciphering the optimal therapeutic strategy for AMPK activation in these contexts, are warranted in order to advance toward addressing critical, unmet clinical needs in NMD patients.
Competitiondate
201701
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ljubicic, Vladimir
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $97,400~ $0~